About this trial
This trial will evaluate whether an experimental drug (NGX-4010) is both safe to use and an effective treatment for the pain resulting from HIV-associated neuropathy.
The study drug contains capsaicin - a substance found in chilli peppers - and is applied to the skin as a patch.
This is a randomised study where people receive either a low concentration patch (acting as placebo) or a high concentration patch for a period of 30 or 60 minutes.
| Official title: | A Multicentre randomized, double-blind, controlled study of NGX-4010 for the treatment of painful HIV-Associated Neuropathy |
|---|---|
| What is this trial studying? | Side effect management |
| Start date: | April 2006 This may be the proposed or expected start date for trials which have not yet started. |
| How many participants will this trial enrol? | 480 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
| How long is this trial planned to go for? | Participants in this trial will be asked to follow the trial protocol for 14 weeks. |
| Who can enrol in this trial? | You may be eligible to participate in this trial if you meet the following criteria:
|
| Links to further information: | |
| Results: | http://treataware.info/content/further-support-marijuana-use-treat-neuro... |
| Can I access this treatment other than by enrolling in this trial? | This is an experimental treatment and not available outside clinical trials. |
| Keywords: | capsaicin, neuropathy, NGX-4010, peripheral neuropathy, side effects and toxicities |
While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.
- Before making the decision to participate in any clinical research, read our background information.
- Email NAPWA if you have any questions or comments about this trial
- Call the Treataware info line if you need further advice
If you've ever participated in a clinical trial, or tried to make sense of scientific research reports, you may have found some of the specialised language confusing to say the least. This Backgrounder (from the Nov-Dec 2002 edition of Positive Living) looks at the vocabulary of clinical trials.